Explore the Agenda
Welcome to our pre-conference day! You can either attend three workshops (A or D, B or E, and C or F) scheduled at various times throughout the day, or choose to attend the Fundamentals of Radiopharmaceuticals Focus Day. If you have any questions about the layout or agenda, feel free to reach out to us at info@hansonwade.com.
Pre-Conference Workshop Day
Taking Emerging Alpha Emitters from Discovery through Development to Scalable Supply in Radioligand Therapy
9:00 am Workshop A
TATs represent an exciting and fast-evolving class of targeted therapies with the potential for high therapeutic impact due to the potent, short-range cytotoxicity of alpha particles. While clinical interest and investment in these agents are growing rapidly, bringing up-and-coming alpha emitters such as 211-At and 212-Pb from early discovery into broad clinical use remains challenging.
This workshop will provide an integrated analysis from scientific foundations through to real-world supply chain considerations, addressing the technical, logistical, and commercial hurdles that must be overcome to enable the future success of TATs.
- Explore the radiophysical properties of promising alpha emitters including astatine-211 and lead-212
- Assess current and emerging industrial-scale production approaches – from cyclotron networks for 211-At to thorium-228-based generator systems for 212-Pb
- Identify challenges in logistics due to short half-lives and regulatory/licensing constraints, and best practices for supply preparedness
- Review the evolving market dynamics for alpha emitters, investment trends, and competitive positioning in the context of a growing radioligand therapy space
–
Outcome – Whitepaper on Alpha Supply Chain Roadmap-collaborative draft outlining strategic recommendations for scalable production and reliable distribution of 211-At and 212-Pb, including infrastructure gaps and potential solutions.
12:00 pm Lunch & Networking
Advancing Safer Tumor-Targeted Radiopharmaceuticals Through Molecular Design & Safety Optimization
1:00 pm Workshop D
Radiopharmaceutical therapies are evolving rapidly, offering unprecedented opportunities for targeted tumor eradication, but these innovations come with unique safety challenges. The therapeutic potential of these agents depends on precise molecular targeting, optimal payload selection, controlled biodistribution, and accurate radiation dosing. Small variations in molecular design or pharmacokinetics can dramatically affect efficacy and off-target toxicity, making the design process both a scientific and clinical imperative.
This workshop will delve into insights regarding:
- Leveraging tumor biology, receptor expression, and disease-specific molecular pathways to optimize targeting moieties and payload combinations, improving selectivity and therapeutic index
- Understanding molecular, cellular, and organ-level toxicity mechanisms across radiopharmaceutical modalities, and implementing chemical, formulation, or dosing strategies to minimize adverse effects
- Using preclinical pharmacology, predictive simulations, and early human data to guide rational candidate selection, optimize safety margins, and accelerate clinical translation
–
Outcome – Development of a framework for safer tumor-targeted radiopharmaceutical design, integrating molecular targeting, payload selection, and toxicity mitigation strategies to guide candidate prioritization and accelerate preclinical-to-clinical translation.
4:00 pm End of Pre-Conference Workshop Day
Fundamentals Focus Day
8:55 am Chair’s Opening Remarks
Transitioning to TRPs: Introducing the Roadmap to Current RLT Success & Understanding Radioisotope Selection Fundamentals
9:00 am Radiopharmaceutical Recap: Landscape Updates, Major Milestones & Trends from Recent Years
- Sharing how the radiopharmaceuticals field is rapidly advancing, with growing clinical data shaping our understanding of pharmacokinetics, efficacy, and safety
- Examining where we stand and where we are heading across the landscape of therapeutic and diagnostic platforms
- Exploring radiation dosimetry, regulatory considerations, and manufacturing – highlighting key learnings and emerging challenges
9:30 am Selecting the Right Radioisotope: Maximizing Therapeutic Effect While Minimizing Risk
- Evaluating isotope properties including half-life and emission type
- Assessing radiochemical behavior for stability and efficacy
- Comparing isotopes for therapeutic versus diagnostic applications
10:00 am Roundtable Discussion – Designing Effective TRP Targets by Exploring Emerging Clinical Candidates & Lessons from Other Targeted Therapies
Join your colleagues for a deep-dive discussion in smaller groups to map out the next generation of TRP targets. You will brainstorm high-potential clinical candidates and cross-pollinate ideas from the ADC space to sharpen selection strategy before sharing your table’s thoughts and discussion back to the group.
- Identifying optimal tumor targets by evaluating density, internalization, and off-target risk
- Exploring current targets under development and their potential clinical impact
- Applying lessons from antibody-drug conjugates and other targeted therapies to guide RLT target selection
10:30 am Morning Break & Networking
Beginning to Build your RLT Toolbox – What is the Strategy for Success?
11:00 am Harnessing the Power of Antibodies, Peptides, & Small Molecules to Optimize RLT Performance
- Comparing antibodies, antibody fragments, peptides, and small molecules for different RLT applications
- Evaluating how moiety choice influences tumor uptake, internalization, and off-target exposure
- Applying practical lessons to match targeting format with clinical objectives and therapeutic strategy
11:30 am Roundtable Discussion – Designing the Ideal Radioligand Therapy by Integrating Isotope, Chelator, & Targeting Moiety Selection
Pull up a chair for this high-energy collaborative session where you will join your industry peers to dissect the “Holy Trinity” of RLT design and solve complex integration puzzles. It’s time to trade insights, challenge traditional selection criteria, and then share your group’s top 3 thoughts and discussion points back to the room!
- Bringing together preclinical and early clinical perspectives to explore how to optimize RLT design for efficacy, safety, and translational readiness
- Balancing isotope properties, emission type, and half-life with clinical objectives
- Selecting chelation strategies to ensure stability, delivery, and safety
- Matching targeting moieties to tumor biology and therapeutic goals
12:30 pm Lunch & Networking
Exploring Biodistribution, Dosimetry & Supply Chain Considerations for Moving to Clinical Trials
1:30 pm Exploring Radiopharmaceutical CMC Processes & Supply Chain Considerations to Guide Development
- Understanding radiochemistry and CMC processes
- Exploring opportunities for downstream optimization
- Navigating challenging supply chains
2:00 pm Designing a Radiopharmaceutical Clinical Trial: Key Considerations from the Start
- Outlining the network of clinical experts who are involved from nuclear medical physicians to medical oncologists
- Key differences in a radiopharma trial
- Radiation safety considerations
- If clinical trials require a clinical sub study/assessment?
- Importance of onsite imaging
2:30 pm Fireside Chat: What I Wish I Knew When Entering Radiopharma
Thinking about entering radiopharma – or wish you’d known more before you did? Join seasoned leaders from R&D, CMC, clinical, and commercial as they share hard-won lessons, practical pitfalls, and insider insights across the entire development journey, and bring your questions to those who’ve navigated it firsthand.
- R&D and Preclinical: novel target choices, targeting molecules, linkers, chelators, preclinical dosimetry and more
- CMC and Regulatory: isotope properties, differences in supply chain, logistics networks, CMC innovations, regulatory considerations and more
- Clinical Development: clinical trial design, working with sites, working with clinical stakeholders, patient centric approaches and more